Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 12Phase 1/2 5Phase NA 4Phase 2/3 3Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 6Leukemia 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Recurrence 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Follicular 2Leukemia, T-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Ewing 1Retinoblastoma 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Etoposide × Clear all
NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00749723 2018-07-20

HIT-REZ-2005

University Hospital, Bonn

Phase 2/3 Completed
174 enrolled
CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Recurrence

NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡